Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tatsuya Toyama

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
Breast Cancer (Tokyo, Japan)|January 14, 2004
p33ING1b and estrogen receptor (ER) alphaTatsuya Toyama, Hirotaka Iwase
Oncogene|March 19, 2003
Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cellsHiroko Yamashita, Hirotaka Iwase, Tatsuya Toyama, et al.
Cancer Research|July 3, 2008
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancerNaoto Kondo, Tatsuya Toyama, Hiroshi Sugiura, et al.
Breast Cancer (Tokyo, Japan)|September 4, 2014
Multi-detector row CT-guided marking technique for breast-conserving therapy of early breast cancer: margin positivity and local control ratesMisugi Urano, Norio Shiraki, Masaki Hara, et al.
Breast Cancer (Tokyo, Japan)|March 28, 2016
Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative studyJunichi Kurebayashi, Tatsuya Toyama, Shuuji Sumino, et al.
Breast Cancer (Tokyo, Japan)|January 25, 2020
Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trialsMinoru Miyashita, Masaya Hattori, Toshimi Takano, et al.
Breast Cancer (Tokyo, Japan)|February 12, 2020
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysisTatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, et al.
Breast Cancer (Tokyo, Japan)|January 10, 2020
Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 editionTetsuhiro Yoshinami, Kei Koizumi, Shigenori E Nagai, et al.
Nagoya Journal of Medical Science|May 14, 2026
A case of reconstruction for triple-negative metaplastic breast cancer that enlarged rapidly during neoadjuvant immunochemotherapyKazuhiro Toriyama, Souji Yoshimura, Ryota Nakamura, et al.
Cancer Research|August 3, 2002
ING1 isoforms differentially affect apoptosis in a cell age-dependent mannerDiego Vieyra, Tatsuya Toyama, Yasuo Hara, et al.
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
Breast Cancer (Tokyo, Japan)|January 14, 2004
p33ING1b and estrogen receptor (ER) alphaTatsuya Toyama, Hirotaka Iwase
Oncogene|March 19, 2003
Naturally occurring dominant-negative Stat5 suppresses transcriptional activity of estrogen receptors and induces apoptosis in T47D breast cancer cellsHiroko Yamashita, Hirotaka Iwase, Tatsuya Toyama, et al.
Cancer Research|July 3, 2008
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancerNaoto Kondo, Tatsuya Toyama, Hiroshi Sugiura, et al.
Breast Cancer (Tokyo, Japan)|September 4, 2014
Multi-detector row CT-guided marking technique for breast-conserving therapy of early breast cancer: margin positivity and local control ratesMisugi Urano, Norio Shiraki, Masaki Hara, et al.
Breast Cancer (Tokyo, Japan)|March 28, 2016
Efficacy and safety of leuprorelin acetate 6-month depot, TAP-144-SR (6M), in combination with tamoxifen in postoperative, premenopausal patients with hormone receptor-positive breast cancer: a phase III, randomized, open-label, parallel-group comparative studyJunichi Kurebayashi, Tatsuya Toyama, Shuuji Sumino, et al.
Breast Cancer (Tokyo, Japan)|January 25, 2020
Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trialsMinoru Miyashita, Masaya Hattori, Toshimi Takano, et al.
Breast Cancer (Tokyo, Japan)|February 12, 2020
First-line endocrine therapy for postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer: a systematic review and meta-analysisTatsunori Shimoi, Yasuaki Sagara, Fumikata Hara, et al.
Breast Cancer (Tokyo, Japan)|January 10, 2020
Dose-dense adjuvant chemotherapy: a systematic review and meta-analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2018 editionTetsuhiro Yoshinami, Kei Koizumi, Shigenori E Nagai, et al.
Nagoya Journal of Medical Science|May 14, 2026
A case of reconstruction for triple-negative metaplastic breast cancer that enlarged rapidly during neoadjuvant immunochemotherapyKazuhiro Toriyama, Souji Yoshimura, Ryota Nakamura, et al.
Cancer Research|August 3, 2002
ING1 isoforms differentially affect apoptosis in a cell age-dependent mannerDiego Vieyra, Tatsuya Toyama, Yasuo Hara, et al.
Pageof 15